1. Medtech Insight
  3. >>Diabetic Care

Market Intel: Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market

 
• By Chrystal Larsen

The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.

Diabetes Flat Icon Set - Insulin Pump, Glucometer, Syringe, Injection Pen, Lancets, Blood Glucose Test COPYRIGHT: Shutterstock: HelgaMariah

The global diabetes management devices market is expected to grow from $9bn in 2015 to $11.2bn by 2020, a CAGR of 4.5%. While blood glucose monitors – continuous or otherwise –account for the largest product segment of the total diabetes market with about 66% of total sales, the smaller, yet highly innovative insulin pump segment is expected to see the biggest growth.

According to a new report by Meddevicetracker, "Global Diabetes Management Devices Market," global sales of glucose meters and CGMs are expected to rise from roughly $6bn...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.